Virchows Archiv

, Volume 462, Issue 6, pp 639–644 | Cite as

ERG expression and prostatic adenocarcinoma

  • Montse Verdu
  • Isabel Trias
  • Ruth Roman
  • Natalia Rodon
  • Beatriz Garcia-Pelaez
  • Miquel Calvo
  • Arturo Dominguez
  • Josep M. Banus
  • Xavier Puig
Original Article

Abstract

ERG gene rearrangement has been identified as a highly specific alteration that is present in 40–50 % of prostate carcinomas. The standardization of an immunohistochemical assay with a novel anti-ERG antibody recently described would have significant diagnostic value. The aims of this study were to identify the incidence of this rearrangement in a Spanish population and to test the specificity of immunohistochemical ERG evaluation for prostate carcinomas. Three prostate tissue microarrays were constructed using radical prostatectomy specimens and related to grade, local invasion, and regional invasion. In addition to samples from malignant cases (160), specimens of prostatic hyperplasia (26) and high-grade prostatic intraepithelial neoplasia (10) were included. Tissue microarrays of 270 samples from most common malignant tumors (breast, colon, lung, and bladder) were also tested. All were analyzed by immunohistochemistry. Seventy-five out of 154 evaluable cases (49 %) of prostate carcinoma showed ERG expression; 52/75 showed strong staining. No ERG expression was observed in any of the high-grade prostatic intraepithelial neoplasia. ERG expression was independent of Gleason score (p = 0.160), extent of invasion (p = 0.517), and regional lymph node involvement (p = 0.816). No ERG expression was found in any other type of tumor, with the exception of one bladder cancer sample that showed focal and weak expression. The frequency of ERG detected in our study correlated with the results published for other Caucasian populations. Strong ERG protein expression was exclusively detected in prostate carcinomas, corroborating the specificity of ERG rearrangements for these tumors. Thus, detecting ERG using immunohistochemistry may be useful in routine practice in pathology departments.

Keywords

ERG rearrangement Prostate cancer Immunohistochemistry Clone EPR3864 TMPRSS2:ERG 

References

  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781. doi:10.1016j/ejca.2009.12.014 PubMedCrossRefGoogle Scholar
  2. 2.
    Perner S, Demichelis F, Beroukhim R et al (2006) TMPRSS2:ERG fusion-associated deletions provide insight into heterogeneity of prostate cancer. Cancer Res 66(17):8337–8341. doi:10.1158/0008-5472.CAN-06-1468 PubMedCrossRefGoogle Scholar
  3. 3.
    Wang J, Cai Y, Ren C, Ittmann M (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66:8347–8351. doi:10.1158/0008-5472.CAN-06-1966 PubMedCrossRefGoogle Scholar
  4. 4.
    Clark JP, Cooper CS (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6:429–439. doi:10.1038/nrurol.2009.127 PubMedCrossRefGoogle Scholar
  5. 5.
    Park K, Tomlins SA, Mudaliar KM et al (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 12(7):590–598. doi:10.1593/neo.10726 PubMedGoogle Scholar
  6. 6.
    Falzarano SM, Zhou M, Carver P et al (2011) ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 459(4):441–447. doi:10.1007/s00428-011-1128-4 PubMedCrossRefGoogle Scholar
  7. 7.
    Chaux A, Albadine R, Toubaji A et al (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 35:1014–1020. doi:10.1097/PAS.0b013e31821e8761 PubMedCrossRefGoogle Scholar
  8. 8.
    R Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/.
  9. 9.
    Verzani J (2004) Using R for introductory statistics. Chapman & Hall/CRC, Boca RatonGoogle Scholar
  10. 10.
    Mosquera JM, Mehra R, Regan MM et al (2009) Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the united states. Clin Cancer Res 15(14):4706–4711. doi:10.1158/1078-0432.CCR-08-2927 PubMedCrossRefGoogle Scholar
  11. 11.
    Magi-Galluzzi C, Tsusuki T, Elson P et al (2011) TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71:489–497. doi:10.1002/pros.21265 PubMedCrossRefGoogle Scholar
  12. 12.
    Miyagi Y, Sasaki T, Fujinami K et al (2010) ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 23:1492–1498. doi:10.1038/modpathol.2010.149 PubMedCrossRefGoogle Scholar
  13. 13.
    Minner S, Enodien M, Sirma H et al (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Can Res 17(18):5878–5888. doi:10.1158/1078-0432.CCR-11-1251 CrossRefGoogle Scholar
  14. 14.
    Mosquera JM, Perner S, Genega EM et al (2008) Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 14(11):3380–3385. doi:10.1158/1078-0432.CCR-07-5194 PubMedCrossRefGoogle Scholar
  15. 15.
    Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP (2012) Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases. Arch Pathol Lab Med 136:935–946. doi:10.5858/arpa.2011-0424-OA PubMedCrossRefGoogle Scholar
  16. 16.
    Han B, Mehra R, Lonigro R et al (2009) Fluorescent in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 22(8):1083–1093. doi:10.1038/modpathol.2009.69 PubMedCrossRefGoogle Scholar
  17. 17.
    Falzarano SM, Navas M, Simmerman K et al (2010) ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod Pathol 23:1499–1506. doi:10.1038/modpathol.2010.150 PubMedCrossRefGoogle Scholar
  18. 18.
    Van Leenders GJ, Boormans JL, Vissers CJ et al (2011) Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 24(8):1128–1138. doi:10.1038/modpathol.2011.65 PubMedCrossRefGoogle Scholar
  19. 19.
    Demichelis F, Fall K, Perner S et al (2007) TMPRSS2-ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26(31):4596–4599. doi:10.1038/sj.onc.1210237 PubMedCrossRefGoogle Scholar
  20. 20.
    Furusato B, Tan S-H, Young D et al (2010) ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 13(3):228–237. doi:10.1038/pcan.2010.23 PubMedCrossRefGoogle Scholar
  21. 21.
    He H, Magi-Galluzzi C, Li J et al (2011) The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with “atypical glands suspicious for cancer”. Am J Surg Pathol 35(4):608–614. doi:10.1097/PAS.0b013e31820bcd2d PubMedCrossRefGoogle Scholar
  22. 22.
    Yaskiv O, Zhang X, Simmerman K et al (2011) The utility of ERG/p63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 35(7):1062–1068. doi:10.1097/PAS.0b013e318215cc03 PubMedCrossRefGoogle Scholar
  23. 23.
    Jiang Z, Li C, Fischer A, Dresser K, Woda BA (2005) Using an AMACR (P504S)/34bE12/p63 cocktail for the detection of small focal prostate carcinoma in needle biopsy specimens. Am J Clin Pathol 123:231–236PubMedCrossRefGoogle Scholar
  24. 24.
    Perner S, Mosquera JM, Demichelis F et al (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882–888PubMedCrossRefGoogle Scholar
  25. 25.
    Scheble VJ, Braun M, Beroukhim R et al (2010) ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol 23:1061–1067. doi:10.1038/modpathol.2010.87 PubMedCrossRefGoogle Scholar
  26. 26.
    Miettinen M, Wang Z-F, Anders P et al (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35:432–441. doi:10.1097/PAS.0b013e318206b67b PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Montse Verdu
    • 1
    • 2
  • Isabel Trias
    • 1
    • 2
    • 3
    • 6
  • Ruth Roman
    • 1
  • Natalia Rodon
    • 1
  • Beatriz Garcia-Pelaez
    • 1
  • Miquel Calvo
    • 4
  • Arturo Dominguez
    • 5
  • Josep M. Banus
    • 5
  • Xavier Puig
    • 1
    • 2
    • 6
  1. 1.BIOPAT, Biopatologia MolecularGrup AssistenciaBarcelonaSpain
  2. 2.Histopat LaboratorisBarcelonaSpain
  3. 3.Hospital Plato Fundacio PrivadaBarcelonaSpain
  4. 4.Statistics DepartmentUniversitat de Barcelona (UB)BarcelonaSpain
  5. 5.Institut Catala d’Urologia i Nefrologia (ICUN)BarcelonaSpain
  6. 6.Hospital de Barcelona, SCIASGrup AssistenciaBarcelonaSpain

Personalised recommendations